Hydroxycitric acid tripotassium

Synonyms: 羟基柠檬酸三钾盐
Hydroxycitric acid tripotassium 是一种口服有效的多靶点、多生物活性有机酸,可激活 Nrf2 和下游分子 GPX4 并提升谷胱甘肽水平,从而抑制铁死亡 (ferroptosis),同时通过激活 Nrf2/Keap1 和 ACLY/NF-κB 信号通路、上调超氧化物歧化酶等抗氧化酶活性并降低 MDA 含量,减轻氧化应激和肾小管上皮细胞凋亡 (apoptosis),改善肺血管和右心室重构,还能同时激活 AMPK 和 mTORC1/S6K 通路,触发未折叠蛋白反应,阻滞癌细胞周期并引起 DNA 片段化。
产品编号: MS-Z80939 纯度: 98.0% CAS No.: 232281-44-6 分子式: C6H5K3O8 分子量: 322.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Hydroxycitric acid tripotassium 是一种口服有效的多靶点、多生物活性有机酸,可激活 Nrf2 和下游分子 GPX4 并提升谷胱甘肽水平,从而抑制铁死亡 (ferroptosis),同时通过激活 Nrf2/Keap1 和 ACLY/NF-κB 信号通路、上调超氧化物歧化酶等抗氧化酶活性并降低 MDA 含量,减轻氧化应激和肾小管上皮细胞凋亡 (apoptosis),改善肺血管和右心室重构,还能同时激活 AMPK 和 mTORC1/S6K 通路,触发未折叠蛋白反应,阻滞癌细胞周期并引起 DNA 片段化。

生物实验数据

生物活性 Hydroxycitric acid tripotassium is an orally effective, multi-target, multi-bioactive organic acid that activates Nrf2 and the downstream molecule GPX4 and elevates glutathione levels, thereby inhibiting ferroptosis; it also activates the Nrf2/Keap1 and ACLY/NF-κB signaling pathways, upregulates the activity of antioxidant enzymes such as superoxide dismutase, and reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improving pulmonary vascular and right ventricular remodeling; moreover, it simultaneously activates AMPK and the mTORC1/S6K pathway, triggering the unfolded protein response, arresting the cancer cell cycle, and inducing DNA fragmentation.
体外研究
(In Vitro)

Hydroxycitric acid (1-100 mM; 72 h) tripotassium 可强效抑制 K562、MEG-01、CML-T1、KYO-1 和 SKH-1 慢性髓系白血病 (CML) 细胞系的增殖,其 IC50 值为 3.73 至 11.34 mM;而在浓度高达 100 mM 时,对正常小鼠胚胎成纤维细胞无影响。
Hydroxycitric acid (0.5-5 mM) tripotassium 可诱导 K562 慢性髓系白血病 (CML) 细胞发生 DNA 片段化。
Hydroxycitric acid (0.5-10 mM; 48-72 h) tripotassium 可在 K562 慢性髓系白血病 (CML) 细胞中诱导 G2/M 期细胞周期阻滞。
Hydroxycitric acid (0.5-5 mM, 24 h) tripotassium 可通过提高 K562、MEG-01、KYO-1 和 SKH-1 型慢性髓系白血病 (CML) 细胞中 T172 的磷酸化水平激活 AMPK,且不改变 AMPK 的总蛋白水平。
Hydroxycitric acid (0.5-1 mM; 24-48 h) tripotassium 可同时激活 AMPK 和 mTORC1 通路,并通过上调 eIF2α 磷酸化水平及 ATF4 表达量,在 K562 慢性髓系白血病 (CML) 细胞中触发未折叠蛋白反应。
Hydroxycitric acid tripotassium (5-10 mM) 可在 5 mM 和 10 mM 浓度下显著抑制缺氧诱导的人肺动脉平滑肌细胞增殖。
Hydroxycitric acid tripotassium (匹配低氧/常氧暴露条件) 可抑制常氧和低氧条件下人肺动脉平滑肌细胞的增殖,且对低氧环境下细胞的抑制作用更强。
Hydroxycitric acid tripotassium (24 h) 显著抑制缺氧诱导的人肺动脉平滑肌细胞迁移。
Hydroxycitric acid tripotassium (过夜处理) 可显著降低低氧诱导的人肺动脉平滑肌细胞中活性氧的生成。
Hydroxycitric acid tripotassium (联合低氧暴露) 可显著降低低氧诱导的人肺动脉平滑肌细胞中缺氧诱导因子-1 (HIF-1) mRNA 的表达。

Cell Cycle Analysis

Cell Line: K562 CML cells
Concentration: 0.5, 5 and 10 mM
Incubation Time: 48 h; 72 h
Result: Caused a significant accumulation of K562 cells in the G2/M phase of the cell cycle after 48 h treatment with 10 mM.
Caused significant accumulation of cells in the G2/M phase after 72 h treatment with 5 mM and 10 mM.

Western Blot Analysis

Cell Line: CML cell lines K562, MEG-01, KYO-1, SKH-1
Concentration: 0.5 and 1 mM (K562); 0.5 mM, 1 mM, and 5 mM (MEG-01, KYO-1, SKH-1)
Incubation Time: 24 h
Result: Significantly increased phosphorylation of AMPKα at T172 in all tested CML cell lines without altering total AMPKα protein levels.
Increased p-AMPKα levels by ~2-, ~6-, and ~4-fold in MEG-01 cells at 0.5 mM, 1 mM, and 5 mM doses, respectively.
Increased p-AMPKα levels by ~1.5-, ~1.2-, and ~1-fold in KYO-1 cells at 0.5 mM, 1 mM, and 5 mM doses, respectively.
Increased p-AMPKα levels by ~30-fold in SKH-1 cells at 5 mM dose.

Western Blot Analysis

Cell Line: K562 CML cells
Concentration: 0.5 and 1 mM
Incubation Time: 24 and 48 h
Result: Increased phosphorylation of AMPKα, ACC, p70 S6 kinase, S6 ribosomal protein, and eIF2α, and increased ATF4 protein levels.
Indicated concurrent activation of the AMPK and mTORC1 pathways, plus activation of the unfolded protein response.\nShowed AMPK and ACLY interacted in K562 cells via co-immunoprecipitation.
Reduced the total level of immunoprecipitated AMPK-ACLY complex, but the ratio of immunoprecipitated ACLY to AMPK remained unchanged compared to untreated controls, indicating no effect on the interaction between the two proteins.

Western Blot Analysis

Cell Line: K562 CML cells
Concentration: 1 mM
Incubation Time: 24 and 48 h
Result: Confirmed a fraction of AMPK co-eluted with ACLY, showing they are part of a common protein complex.
Had no major effect on the migration of this protein complex.
体内研究
(In Vivo)

Hydroxycitric acid (3 mg/kg;口服;每日;25 天) tripotassium 可使慢性髓系白血病异种移植小鼠模型的最终肿瘤体积降低至原来的 1/3,并显著降低肿瘤重量。
Hydroxycitric acid tripotassium (250 mg/kg;腹腔注射;每日给药;持续 4 周) 可显著降低野百合碱诱导的大鼠肺动脉高压,通过抗炎和抗纤维化作用使 RVSP 降低 28.97%,并改善右心室和肺血管重构。
Hydroxycitric acid tripotassium (250 mg/kg;腹腔注射;每日给药;持续 4 周) 可显著减轻大鼠低氧诱导的肺动脉高压,通过抗炎和抗氧化作用使 RVSP 降低 17.5%,并改善右心室及肺血管重构。

Animal Model: NOD.Cg-PrkdcscidIl2rgtm1WjI/SzJ (NSG) (male, 8-10 weeks old)
Dosage: 3 mg/kg
Administration: p.o.; daily; 25 days
Result: Reduced final average tumor volume.
Animal Model: Sprague-Dawley (male, 8-10 weeks old, monocrotaline-induced model)
Dosage: 250 mg/kg/day
Administration: i.p.; daily; 4 weeks
Result: Reduced right ventricular systolic pressure (RVSP) from 47.60 mmHg to 33.81 mmHg.
Decreased right ventricular index from 39.7% to 26.48%.
Decreased right ventricular weight/body weight ratio from 0.87 mg/g to 0.63 mg/g.
Reduced right ventricular fibrotic area from 15.40% to 8.82%.
Attenuated upregulated mRNA levels of α-SMA, collagen-1, and collagen-3.
Reduced pulmonary arteriole medium film layer thickness from 30.14 μm to 21.86 μm.
Decreased vascular wall area ratio from 0.65% to 0.51%.
Reduced serum levels of IL-6 from 121.20 pg/mL to 59.73 pg/mL, and TNF-α from 19.13 pg/mL to 11.82 pg/mL.
Suppressed elevated p-IκBα and p65 protein expressions in lung tissue.
Animal Model: Sprague-Dawley (male, 8-10 weeks old, hypobaric hypoxia-induced model)
Dosage: 250 mg/kg/day
Administration: i.p.; daily; 4 weeks
Result: Reduced RVSP from 42.30 mmHg to 34.9 mmHg.
Decreased right ventricular index from 32.62% to 26.11%.
Reduced right ventricular fibrotic area from 8.94% to 5.80%.
Attenuated upregulated collagen-1 mRNA levels.
Reduced pulmonary arteriole medium film layer thickness from 33.57 μm to 22.29 μm.
Decreased vascular wall area ratio from 0.71% to 0.45%.
Reduced serum IL-1β levels from 66.50 pg/mL to 55.80 pg/mL.
Increased cardiac SOD concentration from 7.31 U/mg to levels significantly higher than hypoxia-only controls.
Reduced cardiac H2O2 concentration from 8.76 mM to levels significantly lower than hypoxia-only controls.
性状 固体
颜色 White to off-white

化学信息

分子量 322.39
分子式 C6H5K3O8
CAS No. 232281-44-6
别名 羟基柠檬酸三钾盐

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 125 mg/mL (387.73 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM3.1018 mL15.5092 mL31.0183 mL77.5458 mL
5 mM0.6204 mL3.1018 mL6.2037 mL15.5092 mL
10 mM0.3102 mL1.5509 mL3.1018 mL7.7546 mL
15 mM0.2068 mL1.0339 mL2.0679 mL5.1697 mL
20 mM0.1551 mL0.7755 mL1.5509 mL3.8773 mL
25 mM0.1241 mL0.6204 mL1.2407 mL3.1018 mL
30 mM0.1034 mL0.5170 mL1.0339 mL2.5849 mL
40 mM0.0775 mL0.3877 mL0.7755 mL1.9386 mL
50 mM0.0620 mL0.3102 mL0.6204 mL1.5509 mL
60 mM0.0517 mL0.2585 mL0.5170 mL1.2924 mL
80 mM0.0388 mL0.1939 mL0.3877 mL0.9693 mL
100 mM0.0310 mL0.1551 mL0.3102 mL0.7755 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础